Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's New OTC Law Leads To Sales Decline In Higher-Risk Drugs

This article was originally published in PharmAsia News

Executive Summary

Two months into Japan's revised Pharmaceutical Affairs Law, drug makers are seeing a drop in sales for drugs with a higher risk of side effects. Similarly, mail-order companies are experiencing a sharp drop-off in sales of nonprescription drugs because of tighter regulations. The law that became effective June1 loosened regulations governing over-the-counter drugs by allowing stores other than pharmacies to sell them. But the law retained a requirement that pharmacists be on duty to explain possible side effects before drugs classified as Category 1 could be sold. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts